RT Journal Article
SR Electronic
A1 Mosley, Mary
T1 ENDURE: Alogliptin Effective and Safe through 2 Years
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 17
SP 22
OP 22
DO 10.1177/155989771317013
UL http://mdc.sagepub.com/content/13/17/22.1.abstract
AB The Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Subjects With Type 2 Diabetes Mellitus study [ENDURE; NCT00856284] showed that there were greater reductions in the primary endpoint of least square mean change from baseline in HbA1C at 104 weeks with two doses of the DPP-4 inhibitor alogliptin compared with the sulfonylurea glipizide.